High-dimensional neural ODE model to characterize clinical pharmacokinetics of MMAE-based antibody-drug conjugates
Year: 2026
Type: article
Abstract: This study investigates Neural ordinary differential equation (NODE) model to describe clinical pharmacokinetic (PK) data from Monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs). ADC PK is composed of four analytes: total antibody (tmAbs), antibody-conjugated MMAE, unconjugated free MMAE (fMMAE), and ADC. Two different model architectures were explored, one that predicts single-state with one NODE model (single-state NODE) and the other that predicts all states with one single NODE model (multiple-states NODE). All the models were trained with single-dose regimen PK datasets at dose levels of 0.1, 0.5, 1.0, 1.8, 2.4 mg/kg. After training, the models could extrapolate to unseen single-dose regimen datasets at dose levels of 0.15 to 3.3 mg/kg and multiple-dose regimen datasets at dose levels of 0.3 to 3.0 mg/kg with various dosing frequencies (Q1W and Q3W) without introducing covariates such as inter-product variability or inter-study variability. The final model performance, assessed as percent prediction error (%PE) was acceptable. For single-state NODE, the average pooled %PE values across studies were 9.4, -11, 6.6, and 40 for total antibodies, antibody-conjugated MMAE, free MMAE, and ADC, respectively. For multiple-states NODE, the average pooled %PE values across studies were 5.2, -14, 17, and 31 for total antibodies, antibody-conjugated MMAE, free MMAE, and ADCs, respectively. The training process and good training practices for a NODE model development and the limitations of the current model were discussed. This study provides proof of concept for training a NODE model on high-dimensional, highly variable real-world PK data.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,390
Funders: National Cancer Institute, National Institute of General Medical Sciences, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Center for Protein Therapeutics, University at Buffalo
Awards: G1413673743, Translational Systems Pharmacokinetic Models of Novel Anticancer Biologics, Pharmacokinetic strategies to increase monoclonal antibody uptake, distribution, and efficacy for treatment of solid tumors, G8455753510, Modulation of antigen pharmacokinetics with pH dependent antibody, The Indiana University-Ohio State University Maternal and Pediatric Precision in Therapeutics Data, Model, Knowledge, and Research Coordination Center (IU-OSU MPRINT DMKRCC), Pharmacokinetic / Pharmacodynamic Optimization of ADC Therapy for Acute Myeloid Leukemia, Polyesters with controlled topologies for probing transcytosis at the gut-blood barrier, Enhancement of ADC selectivity by inverse targeting: Mechanistic studies and optimization
OpenAlex ID: W7235340465
